Table 5.
Pearson’s correlation of MTDH and clinical variables of HCC from TCGA data
| Variables | r | P value |
|---|---|---|
| History_other_ malignancy | -0.090 | 0.089 |
| History_of_neoadjuvant_treatment | 0.009 | 0.864 |
| Tumor_status | 0.05 | 0.360 |
| Relative_family_history_cancer | 0.004 | 0.938 |
| Radiation_therapy_adjuvant | -0.009 | 0.889 |
| Pharmaceutical_tx_adjuvant | 0.015 | 0.816 |
| Post_op_ablation_embolization | 0.080 | 0.220 |
| No_History_of_Primary_Risk_Factors | -0.077 | 0.156 |
| Alcohol_consumption | -0.028 | 0.612 |
| Hemochromatosis | -0.040 | 0.461 |
| Hepatitis_B | 0.090 | 0.096 |
| Hepatitis_C | 0.042 | 0.443 |
| Non_Alcoholic_Fatty_Liver_Disease | 0.008 | 0.880 |
| Smoking | 0.004 | 0.936 |
| Cirrhosis | 0.015 | 0.780 |
| Age (Z) | -0.061 | 0.252 |
| Gender | -0.229 | <0.001 |
| Height | 0.128 | 0.019 |
| Weight | 0.090 | 0.100 |
| Race | -0.071 | 0.188 |
| Ethnicity | -0.007 | 0.891 |
| Histological_type2 | -0.111 | 0.025 |
| Grade | 0.093 | 0.081 |
| Grade2 | 0.078 | 0.142 |
| AJCC_Pathologic_T | -0.026 | 0.619 |
| AJCC_Pathologic_T2 | -0.016 | 0.764 |
| AJCC_Pathologic_T3 | 0.021 | 0.699 |
| AJCC_Pathologic_N | -0.008 | 0.881 |
| AJCC_Pathologic_M | 0.017 | 0.751 |
| Pathologic_Stage | -0.010 | 0.853 |
| Pathologic_Stage2 | -0.009 | 0.868 |
| Pathologic_Stage3 | -0.037 | 0.502 |
| Vascular_invasion | 0.034 | 0.557 |
| Vascular_invasion2 | 0.032 | 0.584 |
| Residual_tumor | 0.052 | 0.331 |
| AFP | -0.075 | 0.217 |
| Platelet | -0.058 | 0.321 |
| Prothrombin | -0.034 | 0.567 |
| Albumin | 0.058 | 0.327 |
| Total_bilirubin | 0.062 | 0.294 |
| Creatinine | 0.083 | 0.157 |
| Ishak_fibrosis_score | 0.099 | 0.153 |
| Child_Pugh_classification_grade | -0.006 | 0.927 |
Pearson’s correlation tests were used to evaluate the correlation between MTDH expression and clinical variables of HCC. A two-tailed P value <0.05 was regarded to be statistically significant.